OSSIO, a medical technology company specialising in bio-integrative implants, has launched its OSSIOfiber 2.5mm Suture Anchors, in a move to broaden its range of metal-free fixation solutions for orthopaedic surgeries.
The new suture anchors are intended to enhance various surgical procedures, such as Brostrom repair, which addresses lateral ankle instability.
The OSSIOfiber 2.5mm Suture Anchors are designed to offer improved pull-out strength, 55% higher than the leading 2.4mm bio-composite suture anchor available in the market.
These implants are engineered without metal, integrating seamlessly into bone and minimising the risk of adverse reactions, said OSSIO.
The design accommodates standard surgical techniques for soft tissue or suture fixation and includes familiar instruments such as drill bits and a slotted drill guide for efficient insertion.
These anchors are suitable for a broad range of orthopaedic applications across different body parts like the foot, ankle, knee, hand, wrist, elbow, and shoulder. They are indicated for use in both adults and children where growth plates have fused or will not be crossed by fixation.
OSSIO CEO Brian Verrier said: “In launching our latest OSSIOfiber platform, we’ve brought to market the first small, fully bio-integrative suture anchor, which outperforms current options for lateral ankle instability and other repairs.
“With this anchor, surgeons can perform these procedures with less impact and better results for patients, while adding fixation strength. The device also rounds out our best-in-class line of implants for soft tissue fixation.”
OSSIOfiber implants utilise Intelligent Bone Regeneration Technology to combine mechanical strength with natural healing through a bio-integrative design. The company aims to continue expanding the application of these implants across various orthopedic segments.
According to OSSIO, OSSIOfiber represents an alternative to traditional metal and absorbable fixation devices, utilising existing reimbursement codes and techniques already familiar to US healthcare providers.
In December 2024, the orthopaedic fixation company raised $27.6m in an equity funding round led by Questa Capital.
